All In Biotech

Investigational drug · Phase 3

DB-1311

Also called: BNT324

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

4

Any phase or sponsor naming "DB-1311"

First trial start

2023

Aug 17, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DB-1311", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Castration-resistant Prostate Cancer
  • Advanced Lung Cancer
  • Solid Tumors
  • Advanced Solid Tumors

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "DB-1311" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Metastatic Castration-resistant Prostate Cancer

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • OpevesostatMK-5684, ODM-208Phase 37 trials

    Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • MevrometostatPF-06821497Phase 33 trials

    Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer

  • 177Lu-NYM032Phase 32 trials

    Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

  • XaluritamigAMG 509Phase 32 trials

    Amgen · Metastatic Castration-resistant Prostate Cancer

  • BMS-986365Phase 31 trial

    Bristol Myers Squibb · Metastatic Castration-resistant Prostate Cancer

  • DeutenzalutamidePhase 31 trial

    AstraZeneca · Metastatic Castration-resistant Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.